The DOI matches its Crossref record.
Novel Nanoliposomal CPT-11 Infused by Convection-Enhanced Delivery in Intracranial Tumors: Pharmacology and Efficacy
Abstract
We hypothesized that combining convection-enhanced delivery (CED) with a novel, highly stable nanoparticle/liposome containing CPT-11 (nanoliposomal CPT-11) would provide a dual drug delivery strategy for brain tumor treatment. Following CED in rat brains, tissue retention of nanoliposomal CPT-11 was greatly prolonged, with >20% injected dose remaining at 12 days for all doses. Tissue residence was dose dependent, with doses of 60 μg (3 mg/mL), 0.8 mg (40 mg/mL), and 1.6 mg (80 mg/mL) resulting in tissue half-life (t1/2) of 6.7, 10.7, and 19.7 days, respectively. In contrast, CED of free CPT-11 resulted in rapid drug clearance (tissue t1/2 = 0.3 day). At equivalent CED doses, nanoliposomal CPT-11 increased area under the time-concentration curve by 25-fold and tissue t1/2 by 22-fold over free CPT-11; CED in intracranial U87 glioma xenografts showed even longer tumor retention (tissue t1/2 = 43 days). Plasma levels were undetectable following CED of nanoliposomal CPT-11. Importantly, prolonged exposure to nanoliposomal CPT-11 resulted in no measurable central nervous system (CNS) toxicity at any dose tested (0.06-1.6 mg/rat), whereas CED of free CPT-11 induced severe CNS toxicity at 0.4 mg/rat. In the intracranial U87 glioma xenograft model, a single CED infusion of nanoliposomal CPT-11 at 1.6 mg resulted in significantly improved median survival (>100 days) compared with CED of control liposomes (19.5 days; P = 4.9 × 10−5) or free drug (28.5 days; P = 0.011). We conclude that CED of nanoliposomal CPT-11 greatly prolonged tissue residence while also substantially reducing toxicity, resulting in a highly effective treatment strategy in preclinical brain tumor models. (Cancer Res 2006; 66(5): 2801-6)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Nanoparticle PEGylation for Imaging and Therapy
Jokerst, J. V., Lobovkina, T., Zare, R. N., & Gambhir, S. S. (2011) · Nanomedicine · doi:10.2217/nnm.11.19 · Cited by 2,046
Polymeric nanoparticles for drug delivery to the central nervous system
Patel, T., Zhou, J., Piepmeier, J. M., & Saltzman, W. M. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.12.006 · Cited by 565
Molecular Imaging with Theranostic Nanoparticles
Jokerst, J. V., & Gambhir, S. S. (2011) · Accounts of Chemical Research · doi:10.1021/ar200106e · Cited by 548
Getting into the Brain: Approaches to Enhance Brain Drug Delivery
Patel, M. M., Goyal, B. R., Bhadada, S. V., Bhatt, J. S., & Amin, A. F. (2009) · CNS Drugs · doi:10.2165/0023210-200923010-00003 · Cited by 461
Vieira, D., & Gamarra, L. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s117210 · Cited by 427
Metadata
- Authors
- Noble, C. O., Krauze, M. T., Drummond, D. C., Yamashita, Y., Saito, R., Berger, M. S., Kirpotin, D. B., Bankiewicz, K. S., & Park, J. W.
- Venue
- Cancer Research
- Published
- 2006-03-01
- Volume
- 66
- Issue
- 5
- Pages
- 2801-2806
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2061225714
- Cited by
- 158
- References
- 0
- FWCI
- 7.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel Nanoliposomal CPT-11 Infused by Convection-Enhanced Delivery in Intracranial Tumors: Pharmacology and Efficacy. https://app.cochat.ai/papers/10.1158/0008-5472.can-05-3535
- The paper
- Noble, C. O., Krauze, M. T., Drummond, D. C., Yamashita, Y., Saito, R., Berger, M. S., Kirpotin, D. B., Bankiewicz, K. S., & Park, J. W. (2006). Novel Nanoliposomal CPT-11 Infused by Convection-Enhanced Delivery in Intracranial Tumors: Pharmacology and Efficacy. Cancer Research. https://doi.org/10.1158/0008-5472.can-05-3535
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.